Recently, SH3YL1 has emerged as a potential biomarker for AKI, particularly in contexts associated with increased oxidative stress, sparking interest in its expression dynamics in bladder cancer patients receiving cisplatin therapy [38]. The gene discussed is SH3YL1; the disease is urinary bladder carcinoma.